The Priority Review

Category

Clinical trials

Trial starts, readouts, holds and designs.

267 stories · page 6 of 23

Stories

  1. Johnson & Johnson reports ICOTYDE achieves 58% ACR20 response in biologic-naïve psoriatic arthritis

    The Phase 3 ICONIC-PsA 1 study met its primary endpoint, with 58% of ICOTYDE-treated patients achieving an ACR20 response versus 41% of placebo at Week 16. Safety data through Week 24 showed no new safety signals and were consistent with the established safety profile of ICOTYDE.

  2. 1.3 percent on BIC/LEN had HIV-1 RNA of 50 copies/mL or more at Week 48; 1.0 percent on B/F/TAF

    In ARTISTRY-2, 1.3 percent of 383 participants switched to bictegravir/lenacapavir had HIV-1 RNA of 50 copies/mL or more at Week 48, versus 1.0 percent of 191 who stayed on Biktarvy. Gilead Sciences has posted the Phase 3 results for adults with HIV-1 who were virologically suppressed.

  3. United Therapeutics registers SUMMIT OLE study

    The study, titled An Open-label Extension Study of Treprostinil Administered Via a Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD), plans to enroll 400 participants and is expected to start in March 2027. It is a Phase 2 and Phase 3 open-label extension aimed at evaluating long-term safety and efficacy.

  4. AstraZeneca registers Phase III trial of AZD6234 in obesity and type 2 diabetes

    The SELENE-Asia study plans to enroll 330 participants and begin recruiting on January 4, 2027. It will evaluate the efficacy and safety of AZD6234 compared with placebo in adults who are overweight or obese, with or without type 2 diabetes mellitus.

  5. Sanofi registers Phase 2 and 3 study of rilzabrutinib in iCVID

    The study, first posted on ClinicalTrials.gov on November 6, 2026, plans to enroll 96 participants and has a planned start date of November 9, 2026. It evaluates efficacy, safety, and tolerability of rilzabrutinib in adults with inflammatory common variable immunodeficiency over four parts, with a planned primary completion date of May 10, 2035.

  6. Jiangsu HengRui registers Phase 3 trial of SHR-3167 vs insulin glargine

    The study plans to enroll 450 insulin-naive type 2 diabetes participants to compare once-weekly SHR-3167 with once-daily insulin glargine. It is planned to start in November 2026 and complete primary outcomes in October 2027.

  7. GlaxoSmithKline posts results of Phase 3b study of rMenB+OMV NZ in adolescents

    Results for the Phase 3b, open-label study of the meningococcal group B vaccine rMenB+OMV NZ were first posted on ClinicalTrials.gov on November 6, 2026, after enrolling 312 participants. The study evaluated the immune response and safety of a booster dose in healthy 10- to 20-year-old participants who were primed with the vaccine during infancy.

  8. Antengene announces first patient dosed in Phase I ATTRACT study of ATG-201

    The company announced dosing began on Nov. 5, 2026 in China. The study is being conducted in China and Australia, and ATG-201 has received Human Research Ethics Committee approval in Australia and completed the Clinical Trial Notification process with the Therapeutic Goods Administration.

  9. Event-free survival 0.557 on ravulizumab and 0.475 on placebo in transplant-associated TMA

    In the Phase 3 trial, with 64 participants analyzed on ravulizumab and 62 on placebo, the event-free survival proportion at Week 26 was 0.557 on ravulizumab and 0.475 on placebo, with a p-value of 0.6386. Alexion's full results for this HSCT-TMA study are now public.

  10. Anaheim Bio launches with €40 million Series A financing to advance ANA-1 for CPPD

    The company said the oversubscribed €40 million Series A financing takes ANA-1 through IND-enabling studies and into Phase 1. Anaheim Bio, spun out of Alesta Therapeutics, expects clinic entry in 2027 and has a runway to 2028, with backing from Droia Ventures, Frazier Life Sciences, RTW, Novartis Venture Fund, RV Invest and Thuja Capital.

  11. Novo Nordisk registers Phase 3 trial of CagriSema in hypertension and obesity

    The study, titled Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) in Participants With Hypertension and Obesity, plans to enroll 1408 participants and is expected to start on November 11, 2026. Participants will receive CagriSema, semaglutide, cagrilintide, or placebo in a randomized, quadruple-masked design.

  12. Sanofi registers Phase 3 study of dupilumab coformulation in atopic dermatitis

    The study, led by Sanofi and collaborating with Regeneron Pharmaceuticals, plans to enroll 150 participants and begin on November 30, 2026. It compares the pharmacokinetics, immunogenicity and safety of dupilumab coformulated with berahyaluronidase alfa to the approved dupilumab formulation in adults and adolescents with moderate-to-severe atopic dermatitis.